See more : Ipsen S.A. (IPN.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Positron Corporation (POSC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Positron Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Telsys Ltd. (TLSY.TA) Income Statement Analysis – Financial Results
- Ryman Healthcare Limited (RYM.NZ) Income Statement Analysis – Financial Results
- Proteak Uno, S.A.B. de C.V. (PKNOF) Income Statement Analysis – Financial Results
- Sigilon Therapeutics, Inc. (SGTX) Income Statement Analysis – Financial Results
- Ananda Development Public Company Limited (ANAN.BK) Income Statement Analysis – Financial Results
Positron Corporation (POSC)
About Positron Corporation
Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 734.67K | 727.58K | 881.95K | 823.75K | 777.96K | 1.45M | 1.47M | 1.63M | 2.80M | 6.66M | 4.62M | 1.45M | 2.13M | 3.31M | 2.21M | 762.00K | 2.78M | 5.07M | 4.68M | 2.54M | 6.72M | 1.53M | 2.01M | 3.53M | 3.58M | 5.30M | 6.10M | 2.40M | 6.60M |
| Cost of Revenue | 1.09M | 809.36K | 749.10K | 662.96K | 592.54K | 1.38M | 1.36M | 1.21M | 1.97M | 6.39M | 4.56M | 1.32M | 2.94M | 2.93M | 1.42M | 1.29M | 1.78M | 4.03M | 3.91M | 2.91M | 4.98M | 1.29M | 520.00K | 1.50M | 2.10M | 3.30M | 3.20M | 400.00K | 2.20M |
| Gross Profit | -353.47K | -81.78K | 132.85K | 160.78K | 185.41K | 63.85K | 104.00K | 424.00K | 829.00K | 277.00K | 59.00K | 127.00K | -813.00K | 381.00K | 790.00K | -526.00K | 997.00K | 1.04M | 768.00K | -366.00K | 1.74M | 240.00K | 1.49M | 2.03M | 1.48M | 2.00M | 2.90M | 2.00M | 4.40M |
| Gross Profit Ratio | -48.11% | -11.24% | 15.06% | 19.52% | 23.83% | 4.42% | 7.09% | 26.01% | 29.60% | 4.16% | 1.28% | 8.78% | -38.24% | 11.51% | 35.70% | -69.03% | 35.86% | 20.56% | 16.40% | -14.41% | 25.91% | 15.70% | 74.10% | 57.49% | 41.31% | 37.74% | 47.54% | 83.33% | 66.67% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 471.00K | 564.00K | 940.00K | 1.32M | 1.28M | 178.00K | 1.03M | 1.36M | 1.17M | 446.00K | 401.00K | 671.00K | 1.04M | 1.13M | 1.07M | 602.00K | 0.00 | 1.31M | 2.23M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.19M | 2.78M | 4.33M | 2.32M | 12.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 186.00K | 419.00K | 285.00K | 1.04M | 1.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.01M | 2.60M | 896.42K | 222.85K | 206.17K | 51.29K | 2.38M | 3.20M | 4.61M | 3.35M | 13.23M | 4.78M | 3.22M | 3.64M | 3.07M | 2.08M | 2.10M | 1.75M | 2.25M | 2.15M | 2.64M | 1.26M | 1.70M | 4.65M | 5.26M | 6.80M | 6.70M | 4.30M | 4.40M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.01M | 2.60M | 896.42K | 222.85K | 206.17K | 51.29K | 2.85M | 3.76M | 5.55M | 4.67M | 14.50M | 4.96M | 7.51M | 7.59M | 4.60M | 2.53M | 2.50M | 2.42M | 3.28M | 3.28M | 3.80M | 1.92M | 1.70M | 5.96M | 7.49M | 7.00M | 6.90M | 4.50M | 4.70M |
| Cost & Expenses | 2.10M | 3.41M | 1.65M | 885.82K | 798.71K | 1.43M | 4.21M | 4.97M | 7.52M | 11.06M | 19.07M | 6.28M | 10.45M | 10.52M | 6.03M | 3.81M | 4.28M | 6.45M | 7.20M | 6.19M | 8.78M | 3.21M | 2.22M | 7.46M | 9.59M | 10.30M | 10.10M | 4.90M | 6.90M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 1.00K | 0.00 | 2.00K | 45.00K | 273.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 144.66K | 46.69K | 0.00 | 0.00 | 0.00 | 0.00 | 1.82M | 2.14M | 1.75M | 1.19M | 43.00K | 1.42M | 687.00K | 199.00K | 860.00K | 985.00K | 157.00K | 103.00K | 324.00K | 93.00K | 6.00K | 0.00 | 525.00K | 0.00 | 0.00 | 0.00 | 0.00 | 800.00K | 800.00K |
| Depreciation & Amortization | 41.90K | 42.00K | 26.65K | 23.55K | 20.10K | 9.56K | 152.00K | 160.00K | 226.00K | 77.00K | 43.00K | 14.00K | 652.00K | 222.00K | 701.00K | 762.00K | 178.00K | 86.00K | 205.00K | 205.00K | 88.00K | 54.00K | 250.00K | 280.00K | 137.00K | 200.00K | 200.00K | 200.00K | 300.00K |
| EBITDA | -1.45M | -2.77M | -568.43K | -38.52K | -656.00 | 22.11K | -609.00K | -4.81M | -5.90M | -4.86M | -10.84M | -4.32M | -8.24M | -7.57M | -3.11M | -2.29M | -1.32M | -1.30M | -2.44M | -3.44M | -1.97M | -1.62M | 38.00K | -3.65M | -5.88M | -4.80M | -4.10M | -2.40M | -600.00K |
| EBITDA Ratio | -197.66% | -362.97% | -83.56% | -4.68% | -0.08% | 1.53% | -176.74% | -194.97% | -160.51% | -64.76% | -311.51% | -332.99% | -209.27% | -121.70% | -43.33% | -333.33% | -47.63% | -72.43% | -46.56% | -134.92% | -51.31% | -104.38% | 1.25% | -98.16% | -159.75% | -88.68% | -67.21% | -100.00% | -13.64% |
| Operating Income | -1.36M | -2.68M | -763.57K | -62.07K | -20.75K | 12.55K | -2.74M | -3.34M | -4.72M | -4.39M | -14.44M | -4.83M | -8.33M | -7.21M | -3.81M | -3.05M | -1.50M | -1.38M | -2.70M | -3.65M | -2.06M | -1.68M | -212.00K | -3.93M | -6.01M | -4.90M | -4.30M | -2.60M | -1.20M |
| Operating Income Ratio | -185.22% | -368.75% | -86.58% | -7.54% | -2.67% | 0.87% | -187.11% | -204.79% | -168.58% | -65.92% | -312.44% | -333.96% | -391.67% | -217.95% | -172.30% | -400.52% | -54.03% | -27.25% | -57.56% | -143.50% | -30.62% | -109.68% | -10.56% | -111.49% | -168.20% | -92.45% | -70.49% | -108.33% | -18.18% |
| Total Other Income/Expenses | -277.95K | -176.08K | 168.50K | 0.00 | 0.00 | 5.00 | 159.00K | -3.77M | -3.23M | -1.73M | 3.52M | -920.00K | -3.91M | -568.00K | -3.01M | 230.00K | -156.00K | 2.27M | -272.00K | -61.00K | 1.48M | -27.00K | 13.00K | -190.00K | -165.00K | -100.00K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -1.64M | -2.86M | -595.08K | -62.07K | -20.75K | 12.56K | -2.58M | -7.10M | -7.96M | -6.12M | -10.92M | -5.75M | -8.98M | -7.78M | -6.83M | -2.82M | 0.00 | 995.00K | -2.83M | -3.66M | -580.00K | -1.70M | -199.00K | -4.12M | -6.18M | -5.00M | -4.00M | -2.50M | 0.00 |
| Income Before Tax Ratio | -223.05% | -392.95% | -67.47% | -7.54% | -2.67% | 0.87% | -176.26% | -435.83% | -284.01% | -91.87% | -236.28% | -397.58% | -422.15% | -235.12% | -308.50% | -370.34% | 0.00% | 19.63% | -60.34% | -144.02% | -8.63% | -111.45% | -9.91% | -116.87% | -172.81% | -94.34% | -65.57% | -104.17% | 0.00% |
| Income Tax Expense | 4.00 | -2.00 | 3.00 | -3.00 | 4.00 | 2.00 | 1.82M | 2.14M | 1.75M | 1.19M | 43.00K | 1.42M | 648.00K | 545.00K | 2.40M | 734.00K | 156.00K | -2.27M | 452.00K | 61.00K | -2.14M | -286.00K | 512.00K | 524.00K | 362.00K | 0.00 | -200.00K | 800.00K | 0.00 |
| Net Income | -1.64M | -2.86M | -595.08K | -62.07K | -20.75K | 12.56K | -2.58M | -7.10M | -7.96M | -6.12M | -10.92M | -5.75M | -8.98M | -7.78M | -6.59M | -3.81M | -1.66M | 892.00K | -2.97M | -3.71M | 81.00K | -1.39M | -724.00K | -4.46M | -6.38M | -5.00M | -3.80M | -3.30M | -1.20M |
| Net Income Ratio | -223.05% | -392.95% | -67.47% | -7.54% | -2.67% | 0.87% | -176.26% | -435.83% | -284.01% | -91.87% | -236.28% | -397.58% | -422.15% | -235.12% | -297.61% | -499.48% | -59.64% | 17.60% | -63.37% | -145.91% | 1.20% | -90.97% | -36.06% | -126.35% | -178.32% | -94.34% | -62.30% | -137.50% | -18.18% |
| EPS | -0.07 | -0.12 | -0.03 | -0.01 | 0.00 | 0.00 | -0.28 | -1.96 | -2.51 | -3.11 | -6.12 | -9.62 | -26.68 | -32.46 | -32.32 | -23.41 | -12.47 | 8.00 | -19.09 | -23.89 | 0.55 | -17.89 | -56.23 | -364.81 | -669.15 | -552.00 | -412.01 | -362.96 | -1.90K |
| EPS Diluted | -0.07 | -0.12 | -0.03 | -0.01 | 0.00 | 0.00 | -0.28 | -1.96 | -2.51 | -3.11 | -6.12 | -9.62 | -26.68 | -32.46 | -32.32 | -23.41 | -12.47 | 6.06 | -19.09 | -23.89 | 0.42 | -17.89 | -56.23 | -364.81 | -669.15 | -552.00 | -412.01 | -362.96 | -1.90K |
| Weighted Avg Shares Out | 24.04M | 23.43M | 18.40M | 10.98M | 10.98M | 10.98M | 9.26M | 3.63M | 3.16M | 1.97M | 1.78M | 597.58K | 336.39K | 239.69K | 203.77K | 162.61K | 132.97K | 144.04K | 155.43K | 155.16K | 148.12K | 77.76K | 12.88K | 12.21K | 9.53K | 9.06K | 9.22K | 9.09K | 630.00 |
| Weighted Avg Shares Out (Dil) | 24.04M | 23.43M | 18.40M | 10.98M | 10.98M | 10.98M | 9.26M | 3.63M | 3.16M | 1.97M | 1.78M | 597.58K | 336.39K | 239.69K | 203.77K | 162.61K | 132.97K | 147.15K | 155.43K | 155.16K | 191.09K | 77.76K | 12.88K | 12.21K | 9.53K | 9.06K | 9.22K | 9.09K | 630.00 |
Positron Corporation Partners With Upbeat Cardiology Solutions to Expand Cardiac PET-CT Offerings
Niagara Falls, NY, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to...
Positron Corporation Launches Prime Rental Program for Pet-Ct Systems
Niagara Falls, NY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to...
Positron Corporation Announces Sale of NeuSight PET-CT Scanner
Niagara Falls, NY, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to...
Positron Corporation Introduces New, Advanced Designed, Economically Priced PET-CT
Niagara Falls, NY, July 25, 2024 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET & PET-CT imaging systems, is pleased to present its new NeuSight PET-CT 3D 64...
Positron Corporation Orders 5 NeuSight PET-CT Scanners for US Market
Niagara Falls, NY, June 26, 2024 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to...
Positron Corporation Announces Attrius® PET System Sale
Niagara Falls, NY, June 18, 2024 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to...
Positron Corporation Joins Cardiac PET Industry Coalition (CPIC)
Niagara Falls, NY, June 14, 2024 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to...
Positron Corporation Enters OEM Supply and Distribution Agreement for NeuSight PET-CT 64 Slice Scanner
Niagara Falls, NY, June 13, 2024 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to...
Positron Corporation Enters Agreement to Acquire FDA 510(k) for NeuSight PET-CT
Niagara Falls, NY, June 12, 2024 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical support services, is pleased...
Positron Corporation Announces Attrius® PET System Sale
Niagara Falls, NY, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET imaging systems and clinical services, is pleased to welcome a prominent cardiovascular practice in...
Source: https://incomestatements.info
Category: Stock Reports